• 1. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 5. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinoxalines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinoxalines

Professional Introduction to (8-Methyl-6-quinoxalinyl)methanol (CAS No. 668275-42-1)

(8-Methyl-6-quinoxalinyl)methanol, identified by its CAS number 668275-42-1, is a significant compound in the field of pharmaceutical chemistry and bioorganic synthesis. This compound belongs to the quinoxaline derivatives, a class of heterocyclic organic compounds that have garnered considerable attention due to their diverse biological activities and potential applications in medicinal chemistry. The presence of a methyl group at the 8-position and a hydroxymethyl group at the 6-position of the quinoxaline core enhances its structural complexity and functional diversity, making it a valuable scaffold for drug discovery and development.

The< strong>quinoxaline moiety is known for its role in various pharmacological contexts, including antimicrobial, antiviral, anti-inflammatory, and anticancer properties. Research has demonstrated that modifications at specific positions within the quinoxaline ring can significantly influence its biological activity. In particular, the introduction of polar functional groups such as hydroxymethyl or methyl groups can alter the compound's solubility, metabolic stability, and binding affinity to biological targets. The< strong>(8-Methyl-6-quinoxalinyl)methanol structure exemplifies this principle, offering a balance between lipophilicity and polarizability that is often conducive to interactions with biological macromolecules.

Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of the interactions between< strong>quinoxaline derivatives and biological targets. Studies employing high-throughput screening (HTS) and structure-based drug design (SBDD) have identified several< strong>quinoxaline-based compounds with promising pharmacological profiles. Among these, derivatives featuring hydroxymethyl or methyl substituents have shown particularly interesting properties in preclinical studies. For instance, modifications at the 6-position can enhance binding to enzymes or receptors involved in critical cellular pathways, while the 8-methyl group can contribute to optimal pharmacokinetic characteristics.

The< strong>CAS No. 668275-42-1 compound has been extensively studied in academic and industrial research settings for its potential as an intermediate in synthesizing more complex pharmaceutical agents. Its versatility as a building block allows for further functionalization through various chemical transformations, including esterification, alkylation, or oxidation reactions. These modifications can tailor the compound's properties to meet specific requirements for drug development, such as improving bioavailability or enhancing target specificity.

In the realm of medicinal chemistry, the< strong>(8-Methyl-6-quinoxalinyl)methanol scaffold has been explored for its ability to modulate key signaling pathways implicated in diseases such as cancer and neurodegenerative disorders. Quinoxaline derivatives have demonstrated efficacy in inhibiting enzymes like kinases or cyclin-dependent kinases (CDKs), which are often overexpressed in tumor cells. Additionally, the hydroxymethyl group provides a site for further derivatization into more potent analogs with improved pharmacological profiles. Researchers have leveraged this flexibility to develop novel inhibitors with enhanced selectivity and reduced toxicity.

The synthesis of< strong>(8-Methyl-6-quinoxalinyl)methanol typically involves multi-step organic reactions starting from readily available precursors. Common synthetic routes include condensation reactions between appropriate aldehydes or ketones with diamines under acidic conditions, followed by functional group transformations to introduce the desired substituents. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making it feasible to produce sufficient quantities for both research purposes and potential clinical trials.

Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and high-performance liquid chromatography (HPLC) are employed to confirm the structural integrity and purity of< strong>CAS No. 668275-42-1. These methods provide critical data on molecular connectivity, functional group assignments, and impurity profiles, ensuring that the compound meets stringent quality standards before being used in downstream applications. High-resolution NMR spectroscopy is particularly valuable for elucidating the detailed structure of quinoxaline derivatives, while HPLC helps assess their chromatographic purity.

The growing interest in< strong>quinoxaline-based therapeutics has spurred numerous collaborations between academic institutions and pharmaceutical companies aiming to discover new drugs targeting unmet medical needs. Preclinical studies using< strong>(8-Methyl-6-quinoxalinyl)methanol or its derivatives have provided insights into their mechanisms of action and potential therapeutic benefits. For example, some studies suggest that certain quinoxaline analogs may inhibit protein-protein interactions essential for disease progression or enhance immune responses against pathogens.

Looking ahead, future research on< strong>CAS No. 668275-42-1 is likely to focus on optimizing its pharmacological properties through structure-activity relationship (SAR) studies. By systematically varying substituents at different positions within the quinoxaline core, researchers can identify analogs with improved efficacy, selectivity, and safety profiles. Additionally, exploring novel synthetic routes may enable more cost-effective production scales suitable for large-scale drug manufacturing.

In conclusion,< strong>(8-Methyl-6-quinoxalinyl)methanol represents a promising compound with significant potential in pharmaceutical applications. Its unique structural features make it an attractive scaffold for developing innovative therapeutics targeting various diseases. As research continues to uncover new biological activities and synthetic strategies for quinoxaline derivatives,< strong>CAS No. 668275-42-1 will remain a key compound in both academic investigations and industrial drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)